These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 9781702)

  • 1. Variability in spatiotemporal gait characteristics over the course of the L-dopa cycle in people with advanced Parkinson disease .
    MacKay-Lyons M
    Phys Ther; 1998 Oct; 78(10):1083-94. PubMed ID: 9781702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
    Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
    Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gait analysis in patients with Parkinson's disease and motor fluctuations: influence of levodopa and comparison with other measures of motor function.
    O'Sullivan JD; Said CM; Dillon LC; Hoffman M; Hughes AJ
    Mov Disord; 1998 Nov; 13(6):900-6. PubMed ID: 9827613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Locomotor response to levodopa in fluctuating Parkinson's disease.
    Moore ST; MacDougall HG; Gracies JM; Ondo WG
    Exp Brain Res; 2008 Feb; 184(4):469-78. PubMed ID: 17828529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levodopa Is a Double-Edged Sword for Balance and Gait in People With Parkinson's Disease.
    Curtze C; Nutt JG; Carlson-Kuhta P; Mancini M; Horak FB
    Mov Disord; 2015 Sep; 30(10):1361-70. PubMed ID: 26095928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gait variability in Parkinson's disease: influence of walking speed and dopaminergic treatment.
    Bryant MS; Rintala DH; Hou JG; Charness AL; Fernandez AL; Collins RL; Baker J; Lai EC; Protas EJ
    Neurol Res; 2011 Nov; 33(9):959-64. PubMed ID: 22080998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting dopa-sensitive and dopa-resistant gait dysfunction in Parkinson's disease: selective responses to internal and external cues.
    Rochester L; Baker K; Nieuwboer A; Burn D
    Mov Disord; 2011 Feb; 26(3):430-5. PubMed ID: 21462258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of levodopa on forward and backward gait patterns in persons with Parkinson's disease.
    Bryant MS; Rintala DH; Hou JG; Lai EC; Protas EJ
    NeuroRehabilitation; 2011; 29(3):247-52. PubMed ID: 22142758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gait variability in Parkinson's disease: levodopa and walking direction.
    Bryant MS; Rintala DH; Hou JG; Collins RL; Protas EJ
    Acta Neurol Scand; 2016 Jul; 134(1):83-6. PubMed ID: 26399376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of pallidal stimulation and levodopa on gait and preparatory postural adjustments in Parkinson's disease.
    Defebvre LJ; Krystkowiak P; Blatt JL; Duhamel A; Bourriez JL; Périna M; Blond S; Guieu JD; Destée A
    Mov Disord; 2002 Jan; 17(1):76-83. PubMed ID: 11835442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison between the effect of intentional modulations and the action of L-dopa on gait in Parkinson's disease.
    Ferrandez AM; Blin O
    Behav Brain Res; 1991 Nov; 45(2):177-83. PubMed ID: 1789925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gastroretentive carbidopa/levodopa, DM-1992, for the treatment of advanced Parkinson's disease.
    Verhagen Metman L; Stover N; Chen C; Cowles VE; Sweeney M
    Mov Disord; 2015 Aug; 30(9):1222-8. PubMed ID: 25847690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors and safe dosage of levodopa for wearing-off phenomenon in Chinese patients with Parkinson's disease.
    Chen H; Fang J; Li F; Gao L; Feng T
    Neurol Sci; 2015 Jul; 36(7):1217-23. PubMed ID: 25616444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gait consistency over a 7-day interval in people with Parkinson's disease.
    Urquhart DM; Morris ME; Iansek R
    Arch Phys Med Rehabil; 1999 Jun; 80(6):696-701. PubMed ID: 10378498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recuperation of slow walking in de novo Parkinson's disease is more closely associated with increased cadence, rather than with expanded stride length.
    Kwon KY; Lee HM; Kang SH; Pyo SJ; Kim HJ; Koh SB
    Gait Posture; 2017 Oct; 58():1-6. PubMed ID: 28692855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of orally dissolving carbidopa/levodopa (Parcopa) to conventional oral carbidopa/levodopa: A single-dose, double-blind, double-dummy, placebo-controlled, crossover trial.
    Ondo WG; Shinawi L; Moore S
    Mov Disord; 2010 Dec; 25(16):2724-7. PubMed ID: 20925074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of withdrawal of antiparkinson medication on gait and clinical score in the Parkinson patient.
    Pedersen SW; Eriksson T; Oberg B
    Acta Neurol Scand; 1991 Jul; 84(1):7-13. PubMed ID: 1927264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three-dimensional gait biomechanics in Parkinson's disease: evidence for a centrally mediated amplitude regulation disorder.
    Morris M; Iansek R; McGinley J; Matyas T; Huxham F
    Mov Disord; 2005 Jan; 20(1):40-50. PubMed ID: 15390033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abnormalities in the stride length-cadence relation in parkinsonian gait.
    Morris M; Iansek R; Matyas T; Summers J
    Mov Disord; 1998 Jan; 13(1):61-9. PubMed ID: 9452328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Temporal stability of gait in Parkinson's disease.
    Morris ME; Matyas TA; Iansek R; Summers JJ
    Phys Ther; 1996 Jul; 76(7):763-77; discussion 778-80. PubMed ID: 8677280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.